Vulvovaginal candidas during pregnancy (featires of the therapy in the first trimester)
Objective. Evaluation method of therapy for pregnant women, with vulvovaginal candidiasis, with a combination of oral and intravaginal introduction polyene macrolide – natamycin.Borovikov I.O., Kutsenko I.I., Ermolaeva A.S.
Subjects and methods. The results of treatment in 110 pregnant women, patients with invasive vulvovaginal 10-12 weeks gestation: group 1 (n = 55) therapy with natamycin intravaginal at a dose of 100 mg 1 times daily for 6 days; Group 2 (n = 55) had combined treatment natamicinum intravaginal at a dose of 100 mg 1 times daily for 6 days + natamicinum peroral at a dose of 100 mg 4 times daily for 10 days. Direct microscopy, measuring the pH of the vagina, cultural method was using.
Results. Found that the combined intake of natamicinum (oral and intravaginal reception) increases the clinical efficacy of therapy vulvovaginal candidiasis in 1.7 ± 0.12, and microbiological -1.3 ± 0.1 times.
Conclusion. Application of combined therapy antimycotics reasonable etiologically (simultaneous vaginal disinfection and colon) with polyene macrolides natamycin has the fewest side effects, absence of adverse effects on the fetus, and helps improve clinical microbiological efficacy of treatment in patients vulvovaginal invasive.
Keywords
vulvovaginal candidiasis
antimycotics
polyene macrolides
natamycin
pregnancy
first trimester
References
1. Серов В.Н., Тютюнник В.Л. Вульвовагинальный кандидоз: особенности течения и принципы лечения. Фарматека. 2015; 15: 38-43. [Serov V.N., Tyutyunnik V.L. Vulvovaginal candidiasis: the features of the course and the principles of treatment. Farmateka. 2015; 15: 38-43. (in Russian)]
2. Тютюнник В.Л., Карапетян Т.Э., Балушкина А.А. Современные принципы профилактики и лечения вульвовагинального кандидоза. Русский медицинский журнал. 2010; 18(19): 1186-90. [Tyutyunnik V.L., Karapetyan T.E., Balushkina A.A. Modern principles of prevention and treatment of vulvovaginal candidiasis. Russian medical journal. 2010; 18(19): 1186-90. (in Russian)]
3. Chatwani A., Mehta R., Hassan S. Rapid testing for vaginal yeast detection: a prospective study. Am. J. Obstet. Gynecol. 2012;196(4): 309-14.
4. Прилепская В.Н., Байрамова Г.Р. Вульвовагинальный кандидоз. Клиника, диагностика, принципы терапии. М.: ГЭОТАР-Медиа; 2010. 80с. [Prilepskaya V.N., Bayramova G.R. Vulvovaginal candidiasis. Clinic, diagnosis, principles of therapy. Moscow: GEOTAR-Media; 2010. 80p. (in Russian)]
5. Малова И.О., Петрунин Д.Д. Натамицин — противогрибковое средство класса полиеновых макролидов с необычными свойствами. Вестник дерматологии и венерологи. 2015; 3: 161-84. [Malova I.O., Petrunin D.D. Natamycin is an antifungal agent of the class of polyene macrolides with unusual properties. Vestnik dermatologii i venerologi. 2015; 3: 161-84. (in Russian)]
6. Kennedy M., Sobel J. Vulvovaginal сandidiasis сaused by non-albicans Candida species: new insights. Curr. Infect. Dis. Rep. 2013; 12(6): 465-70.
7. Fаlagas M., Betsi G., Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J. Antimicrob. Chemother. 2011; 58(2): 266-72.
8. Stock I. Fungal diseases of vulva and vagina caused by Candida species. Med. Monatsschr. Pharm. 2010; 33(9): 324-33.
9. Арзуманян В., Мальбахова Е.Т., Магаршак О.О., Осокина О.В. Мониторинг эффективности натамицина и азолов in vitro по отношению к штаммам дрожжевых грибов, выделенных с разных типов эпителия. Вопросы гинекологии, акушерства и перинатологии. 2015; 14(4): 58-63. [Arzumanyan V., Malbahova E.T., Magarshak O.O., Osokina O.V. Monitoring the efficacy of natamycin and azoles in vitro against strains of yeast fungi isolated from different types of epithelium. Voprosyi ginekologii, akusherstva i perinatologii. 2015; 14(4): 58-63. (in Russian)]
10. Мозговая Е.В., Талалаева Н.Е., Маругина Е.А., Рыбина Е.В. Антимикотическая терапия кандидозного вульвовагинита у беременных. Доктор.Ру. 2014; 8(ч.1): 57-63. [Mozgovaya E.V., Talalaeva N.E., Marugina E.A., Ryibina E.V. Monitoring the efficacy of natamycin and azoles in vitro against strains of yeast fungi isolated from different types of epithelium. Doktor.Ru. 2014; 8(p.1): 57-63. (in Russian)]
11. Kauffman C., Pappas P., Sobel J., Dismukes W., eds. Essentials of clinical mycology. 2nd ed. New York: Springer; 2016.
12. Gonçalves B., Ferreira C., Alves C.T., Henriques M., Azeredo J., Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016; 42(6): 905-27.
13. Карась И.Ю., Гришакова В.А., Равинг Л.С., Карась Д.В., Красильникова К.С. Вагинальный кандидоз – медико-социальные, психологические и этиологические аспекты. Мать и дитя в Кузбассе. 2006; 2: 32-4. [Karas I.Yu., Grishakova V.A., Raving L.S., Karas D.V., Krasilnikova K.S. Vaginal candidiasis — medico-social, psychological and etiological aspects. Mat i ditya v Kuzbasse. 2006; 2: 32-4. (in Russian)]
14. Ehrström S., Kornfeld D., Rylander E. Perceived stress in women with recurrent vulvovaginal candidiasis. J. Psychosom. Obstet. Gynaecol. 2007;28(3): 169-76.
15. Малова И.О., Кузнецова Ю.А. Современные особенности клинического течения урогенитального кандидоза и анализ антимикотической чувствительности грибов рода Candida. Вестник дерматологии и венерологии. 2015; 2: 68-75. [Malova I.O., Kuznetsova Yu.A. Modern features of the clinical course of urogenital candidiasis and an analysis of the antimycotic sensitivity of fungi of the genus Candida. Vestnik dermatologii i venerologii. 2015; 2: 68-75. (in Russian)]
16. Jobst D., Kraft K. Candida species in stool, symptoms and complaints in general practice – a cross-sectional study of 308 outpatients. Mycoses. 2006; 49(5):415-20.
17. Czeizel A.E., Kazy Z., Vargha P. A case-control teratological study of vaginal natamycin treatment during pregnancy. Reprod. Toxicol. 2003; 17(4): 387-91.
18. Levinskas G.J., Ribelin W.E., Shaffer C.B. Acute and chronic toxicity of pimaricin. Toxicol. Appl. Pharmacol. 1966; 8(1): 97-109.
Received 06.04.2018
Accepted 28.04.2018
About the Authors
Borovikov Igor O., MD, PhD, Department of Obstetrics and Gynecology, Kuban State Medical University, Ministry of Health of Russia.350063, Russia, Krasnodar, Sedina str. 4. E-mail: bio2302@gmail.com
Kutsenko Irina I., MD, Professor, Head of Department of Obstetrics and Gynecology, Kuban State Medical University, Ministry of Health of Russia.
350063, Russia, Krasnodar, Sedina str. 4
Ermolaeva Anna Savvichna, Ph.D., Associate Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov
First Moscow State Medical University, Ministry of Health of Russia. 119146, Russia, Moscow, Bolshaya Pirogovskaya str. 19, bld. 1
For citations: Borovikov I.O., Kutsenko I.I., Ermolaeva A.S. Vulvovaginal candidas during pregnancy (featires of the therapy in the first trimester).
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (5): 116-21. (in Russian)
https://dx.doi.org/10.18565/aig.2018.5.116-121
Similar Articles
